Amicogen, Inc. (KOSDAQ:092040)
South Korea · Delayed Price · Currency is KRW 1,863.00
-27.00 (-1.43%)
Apr 29, 2026, 11:40 AM KST
Amicogen Revenue
In the year 2025, Amicogen had annual revenue of 41.98B KRW, down -75.82%. Amicogen had revenue of 10.87B in the quarter ending December 31, 2025, a decrease of -80.88%.
Revenue
41.98B
Revenue Growth
-75.82%
P/S Ratio
3.17
Revenue / Employee
177.89M
Employees
236
Market Cap
133.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.98B | -131.62B | -75.82% |
| Dec 31, 2024 | 173.60B | 13.70B | 8.57% |
| Dec 31, 2023 | 159.90B | 15.61B | 10.82% |
| Dec 31, 2022 | 144.30B | 19.41B | 15.55% |
| Dec 31, 2021 | 124.88B | 9.02B | 7.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 195.27B |
| JETEMA, | 76.90B |
| CG Invites | 27.39B |
| GeneOne Life Science | 23.04B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.33B |
| ENCell | 5.26B |